Postdoctoral position in T cell tumor immunology Freiburg Vollzeit Universität Freiburg Head of Cellular Genetics Biberach an der Riß Vollzeit Boehringer Ingelheim Academic research assistant (m/f/x) Saarbrücken Vollzeit Universität des Saarlandes
Universität Freiburg
Our team studies biological signaling and protein function with a focus on proteolysis on a proteome-wide scale using mass spectrometry. As part of the SFB1403 (www.sfb1403.uni-koeln.de), we are using termini enrichment approaches to identify new proteolytic processing events and their function in regulated cell death (RCD). The project further aims to deconvolute the activities of different caspases in distinct RCD pathways using optogenetic tools.
Your tasks
Your profile
Our offer
Please submit your application, including a cover letter with brief description of motivation (1 page), your CV, M.Sc. and B.Sc. certificates with transcripts of record and contact details of two referees, as a single pdf file.
We are particularly pleased to receive applications from women for the position advertised here.
Please send your application in English including supporting documents mentioned above citing the reference number 00003503, by 15.01.2024 at the latest. Please send your application to the following address in written or electronic form:
Universität Freiburg
Biologie II/Biochemie/Funktionelle Proteomik
Prof. Dr. P. Huesgen
Schänzlestr., 1
79104 Freiburg
E-mail: pitter.huesgen@biologie.uni-freiburg.de
For further information, please contact Prof. Dr. Pitter Huesgen on the phone number +49 761 203-2690 or E-Mail pitter.huesgen@biologie.uni-freiburg.de.
Postdoctoral position in T cell tumor immunology Freiburg Vollzeit Universität Freiburg Head of Cellular Genetics Biberach an der Riß Vollzeit Boehringer Ingelheim Academic research assistant (m/f/x) Saarbrücken Vollzeit Universität des Saarlandes
PhD Position (all genders welcome) Göttingen Vollzeit Georg-August-Universität Göttingen Technician Early Translational Sciences (ETS) (m/f/d) München Vollzeit Novartis